TPST Tempest Therapeutics, Inc.

NASDAQ
$0.83

Tempest Therapeutics, Inc. (TPST) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -26.0% since its last earnings release on August 13, 2026.

Tempest Therapeutics Missed Consensus Estimates
Thursday, August 13, 2026 · 4:25 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:25 PM ET
Earnings Whisper
-
vs ($0.32)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.09

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.